Agmon

Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

Retrieved on: 
Thursday, February 2, 2023
Banking, Professional Services, Finance, MRVC, Israel Corporation, Gornitzky & Co., First International Bank, Stern, DSP Group, Stock dilution, Intermolecular force, Tidewater, Cronyism, NYSE, Acquisition, Immersion Corporation, File, Behavior, Culture, Letter, Fear, Agmon, Rosenzweig, MRV Communications, Immersion, IMI, TASE, Lodging, TDW, Financial adviser, Management, Renewable energy, Security (finance), Holding company, Stratasys

With this context in mind, the urgent need for change at Nano Dimension is as much about future risks as past underperformance.

Key Points: 
  • With this context in mind, the urgent need for change at Nano Dimension is as much about future risks as past underperformance.
  • In light of investor unrest, we also fear Mr. Stern may try to dilute shareholders in order to place shares in friendly hands.
  • In our view, it is time to add truly independent directors who are committed to maximizing value for all shareholders.
  • We are prepared to invest whatever resources and time it will take to catalyze boardroom change for the benefit of all Nano Dimension’s shareholders and stakeholders.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

Retrieved on: 
Monday, November 22, 2021
Lung, Pregnancy, Disease, Company, Woman, Recurrence, Kidney, SDF, Agmon, Immunoglobulin G, Commercialization, Immunity, GLOBE, Contract, Food, HIV, Liver, Heart, Pancreas, DLA Piper, Private Securities Litigation Reform Act, Business architecture, Bleeding, Bank Hapoalim, Food and Drug Administration, AAT, KMDA, TASE, Chickenpox, Coronavirus, Forward-looking statement, Platelet, Partnership, Post-exposure prophylaxis, HBV, Transplant, FDA, Person, Therapy, Growth, Patient, Innova (video game company), Liver transplantation, Industry, Acquisition, Immunodeficiency, Plasma, 6, COVID-19, Organ transplantation, SVB Leerink, EMA, Knowledge, Antibody, CDC, Hepatitis B virus, ITP, NASDAQ, Fine chemical, Financial services, Pharmaceutical industry, Vaccine

WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.

Key Points: 
  • WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.
  • "The acquisition of this FDA-approved commercial portfolio represents a critical strategic and synergistic transaction and growth driver for Kamada, said Amir London, Kamadas Chief Executive Officer.
  • To partially fund the acquisition costs, Kamada has secured a $40 million credit facility from Bank Hapoalim, Israels leading commercial bank.
  • Kamada Ltd. (the Company) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

Sale and Purchase Agreement Signed for the Sale of Delek Drilling's Stake in the Tamar Gas Field Offshore Israel

Retrieved on: 
Thursday, September 2, 2021
Company, Government, JPMorgan Chase, Electricity, Aphrodite, Mubadala Investment Company, Petroleum, Agmon, Natural gas, Leviathan, TEL, Coal, Delek, Sale, CEO, NSAI, Values-based innovation, Mediterranean Basin

TEL AVIV, Sept. 2, 2021 /PRNewswire/ -- Delek Drilling of Israel has announced the signing of a Sale and Purchase Agreement ("SPA") with Mubadala Petroleum of Abu Dhabi, UAE for the sale of Delek Drilling's 22% non-operated stake in the Tamar gas field offshore Israel.

Key Points: 
  • TEL AVIV, Sept. 2, 2021 /PRNewswire/ -- Delek Drilling of Israel has announced the signing of a Sale and Purchase Agreement ("SPA") with Mubadala Petroleum of Abu Dhabi, UAE for the sale of Delek Drilling's 22% non-operated stake in the Tamar gas field offshore Israel.
  • As consideration for the interest in the Tamar field, Mubadala Petroleum will pay Delek Drilling US$1.025 billion, subject to certain adjustments.
  • The current partners in the Tamarproject are Delek Drilling (22%), Chevron (operator, 25%), Isramco (28.75%), Tamar Petroleum (16.75%), Dor Gas (4%) and Everest (3.5%).
  • Under the Gas Framework, outlined by the Government of Israel, Delek Drilling is obliged to sell all of its holdings in Tamar by the end of 2021.

Sale and Purchase Agreement Signed for the Sale of Delek Drilling's Stake in the Tamar Gas Field Offshore Israel

Retrieved on: 
Thursday, September 2, 2021
Company, Government, JPMorgan Chase, Electricity, Aphrodite, Mubadala Investment Company, Petroleum, Agmon, Natural gas, Leviathan, TEL, Coal, Delek, Sale, CEO, NSAI, Values-based innovation, Mediterranean Basin

TEL AVIV, Sept. 2, 2021 /PRNewswire/ -- Delek Drilling of Israel has announced the signing of a Sale and Purchase Agreement ("SPA") with Mubadala Petroleum of Abu Dhabi, UAE for the sale of Delek Drilling's 22% non-operated stake in the Tamar gas field offshore Israel.

Key Points: 
  • TEL AVIV, Sept. 2, 2021 /PRNewswire/ -- Delek Drilling of Israel has announced the signing of a Sale and Purchase Agreement ("SPA") with Mubadala Petroleum of Abu Dhabi, UAE for the sale of Delek Drilling's 22% non-operated stake in the Tamar gas field offshore Israel.
  • As consideration for the interest in the Tamar field, Mubadala Petroleum will pay Delek Drilling US$1.025 billion, subject to certain adjustments.
  • The current partners in the Tamarproject are Delek Drilling (22%), Chevron (operator, 25%), Isramco (28.75%), Tamar Petroleum (16.75%), Dor Gas (4%) and Everest (3.5%).
  • Under the Gas Framework, outlined by the Government of Israel, Delek Drilling is obliged to sell all of its holdings in Tamar by the end of 2021.